title: The immunosenescent phenotype in mice and humans can be defined by alterations in the natural immunity reversal by immunomodulation with oral AM3.
abstract: The reactivities of monocyte/macrophages and natural killer (NK) cells (natural immunity) were evaluated following the administration of the biological response modifier AM3. The lower number of macrophages and NK cells in middle-aged mice (MAM) compared to young adult mice (YAM) were significantly elevated following AM3 treatment to equal or greater than YAM values. Both macrophage and NK cell cytotoxicity peaked at two days following AM3 treatment and remained elevated over control values for up to 8 days following a four days treatment regimen by the oral route. Of particular interest was the clinical effect of AM3 treatment in chronic bronchitis (CB) patients and various aged volunteers. In middle-aged patients with chronic bronchitis (MACBpts) AM3 treatment resulted in significant increases in the number of monocytes as well as their phagocytic and chemotactic activity. Differential NK cell cytotoxicities were observed in MACBpts compared to middle-aged healthy adults (MAHA) and young healthy adults (YHA). Cytotoxicity in YHA was 2-fold higher than MAHA and 5-fold higher than MACBpts. The depressed number of NK cells in MACBpts was reversed following the AM3 treatment to near NK cell levels in YHA. These observations help to explain how AM3 aids in the restoration of natural cellular immunity and its possible application as an adjuvant to bacterial & viral vaccines as well as in the treatment CB.
authors.affiliation: Dpt. of Clinical Research and Development, Immunology, I.F. Cantabria, Madrid, Spain.
authors.forename: V G
authors.initials: VG
authors.lastname: Villarrubia
authors.forename: M C
authors.initials: MC
authors.lastname: Moreno Koch
authors.forename: C
authors.initials: C
authors.lastname: Calvo
authors.forename: S
authors.initials: S
authors.lastname: González
authors.forename: M
authors.initials: M
authors.lastname: Alvarez-Mon
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000375:Aging / Q000276:immunology*; D000818:Animals; D001991:Bronchitis / Q000188:drug therapy / Q000276:immunology; D002130:Calcium Phosphates / Q000494:pharmacology*; D002908:Chronic Disease; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006020:Glycopeptides / Q000494:pharmacology*; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects* / Q000276:immunology*; D007155:Immunologic Factors / Q000276:immunology / Q000494:pharmacology; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D017737:Macrophages, Peritoneal / Q000187:drug effects; D008297:Male; D051379:Mice; D008875:Middle Aged
chemical_list: D000276:Adjuvants, Immunologic; D002130:Calcium Phosphates; D006020:Glycopeptides; D007155:Immunologic Factors; C038773:Immunoferon